SS-31

SS-31 (pharmaceutical name: elamipretide) was designed in the early 2000s by Hazel Szeto at Weill Cornell Medical College with a precise objective: reach the inner mitochondrial membrane — where most antioxidants cannot penetrate — and stabilize it from the inside. The peptide is small, cell-permeable, and accumulates in mitochondria at concentrations up to 1,000-fold higher than in the cytoplasm. Its primary target is cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane that is essential for organizing the electron transport chain complexes responsible for ATP production.

In damaged or aging mitochondria, cardiolipin becomes oxidized, destabilizing the electron transport chain and creating a vicious cycle: impaired mitochondria produce more free radicals, which damage more cardiolipin, which further impairs the mitochondria. SS-31 breaks this cycle by binding directly to cardiolipin, restoring the structural organization of the electron transport chain, improving ATP output, and reducing electron leakage — the source of reactive oxygen species. The result is not more fuel being burned, but existing fuel being burned more cleanly and efficiently.

SS-31 has progressed through Phase 2 and Phase 3 clinical trials for primary mitochondrial myopathy, Barth syndrome, and heart failure. Results have been mixed, with some trials showing significant benefits and others missing primary endpoints. For healthy individuals the effect is described as a restoration of baseline energy rather than a stimulant. For those with chronic fatigue or mitochondrial dysfunction, the response can be transformative — users describing 50% improvements in cognitive function and physical stamina within the first two weeks of daily protocol.

Community Experiences

"SS-31 is the single most effective treatment I have tried for improving energy. It has improved my cognitive function by 50 percent. The improvements appeared within the first two weeks." — r/cfs

"After a couple of weeks, I can genuinely say that I feel my mitochondria is getting back on track. The SS-31 seems to heal the remaining cracks." — r/cfs

"Not just an energy peptide — it works by fixing mitochondrial structure. When cardiolipin is damaged, everything falls apart. SS-31 is the thing that puts it back together." — r/BodyOptimization

Mitochondrial cardiolipin stabilization research for cellular energy

Frequently Asked Questions

Is SS-31 the same as elamipretide? Yes. SS-31 is the research name, elamipretide is the pharmaceutical name. They refer to the same molecule.

Has SS-31 been through clinical trials? Yes. Multiple Phase 2 and Phase 3 trials for primary mitochondrial myopathy, Barth syndrome, and heart failure. Results have been mixed — some trials showed significant benefits, others missed primary endpoints.

How long does SS-31 take to work? Research protocols report noticeable effects within 1 to 3 weeks, particularly for cognitive function and energy in fatigued individuals. Athletic performance benefits may take 4 to 6 weeks to fully manifest.

Is SS-31 safe? SS-31 has been tested in hundreds of participants across clinical trials with a favorable safety profile. No serious adverse effects have been attributed to the peptide in published research.

Stacking Suggestions

• MOTS-c for metabolic regulation and AMPK activation alongside SS-31's structural mitochondrial repair
• NAD+ for providing the electron transport chain cofactor while SS-31 optimizes chain efficiency
• 5-Amino-1MQ for metabolic acceleration through a complementary mechanism
• Epitalon for telomere support and anti-aging alongside mitochondrial optimization
• BPC-157 for tissue repair while SS-31 focuses on cellular energy production

Get Your BioStack →